Clinical trial
Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
NCT00321672 · NeurogesX, Industry · Completed
Key facts
| NCT number | NCT00321672 |
|---|---|
| Title | Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy |
| Official title | A Multicenter Randomized, Double-Blind, Controlled Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy |
| Lead sponsor | NeurogesX, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pain, HIV Infections, Peripheral Nervous System Diseases |
| Intervention type | Drug |
| Interventions | NGX-4010, 8% capsaicin patch, 0.04% capsaicin patch |
| Enrollment | 494 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | May 4, 2006 |
| Last update posted | Jun 14, 2011 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: